Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RNA

Avidity Biosciences Inc

Dec 20 • 04:00PM ET

31.82

Dollar change +0.77
Percentage change 2.48	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA VRTX SRPT ALNY IONS ARWR NBIX BLUE EXEL SGMO

| Held by: VTI IWM VXF XBI VB VBR IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.90	Insider Own	9.07%	Shs Outstand	118.90M	Perf Week	-2.06%
Market Cap	3.89B	Forward P/E	-	EPS next Y	-3.21	Insider Trans	-5.64%	Shs Float	108.48M	Perf Month	-27.10%
Income	-280.49M	PEG	-	EPS next Q	-0.79	Inst Own	101.10%	Short Float	13.77%	Perf Quarter	-26.85%
Sales	10.12M	P/S	384.44	EPS this Y	1.49%	Inst Trans	15.92%	Short Ratio	12.26	Perf Half Y	-19.77%
Book/sh	12.64	P/B	2.52	EPS next Y	-12.10%	ROA	-25.34%	Short Interest	14.94M	Perf Year	278.81%
Cash/sh	12.99	P/C	2.45	EPS next 5Y	-	ROE	-27.76%	52W Range	8.37 - 56.00	Perf YTD	251.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-57.60%	ROI	-18.61%	52W High	-43.18%	Beta	0.98
Dividend TTM	-	Quick Ratio	17.76	Sales past 5Y	148.90%	Gross Margin	73.78%	52W Low	280.17%	ATR (14)	2.39
Dividend Ex-Date	-	Current Ratio	17.76	EPS Y/Y TTM	3.08%	Oper. Margin	-3209.35%	RSI (14)	31.67	Volatility	6.88% 6.02%
Employees	253	Debt/Eq	0.01	Sales Y/Y TTM	-0.19%	Profit Margin	-2772.45%	Recom	1.09	Target Price	68.27
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	7.77%	Payout	-	Rel Volume	2.39	Prev Close	31.05
Sales Surprise	-42.61%	EPS Surprise	8.63%	Sales Q/Q	-17.10%	Earnings	Nov 07 AMC	Avg Volume	1.22M	Price	31.82
SMA20	-14.68%	SMA50	-25.02%	SMA200	-14.38%	Trades		Volume	2,906,533	Change	2.48%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Initiated	H.C. Wainwright	Buy	$72
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$67
Sep-24-24	Initiated	Goldman	Buy	$59
Aug-28-24	Initiated	Barclays	Overweight	$63
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29
Sep-07-21	Initiated	Evercore ISI	Outperform	$50
Jun-17-21	Initiated	Needham	Buy	$50
Apr-26-21	Resumed	Credit Suisse	Outperform	$37
Jul-07-20	Initiated	Wells Fargo	Overweight	$60
Jul-07-20	Initiated	Wells Fargo	Overweight
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform	$34
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform

Show Previous Ratings

Dec-20-24 05:00PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-26-24 10:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Nov-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-13-24 04:07PM	Avidity Bio Has Surged 416% This Year And That's Before Today's 'Game-Changing' News (Investor's Business Daily) +12.35%
Nov-12-24 07:00AM	Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations (PR Newswire)
06:10PM	Loading…
Nov-07-24 06:10PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
Nov-06-24 10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:27AM	An RNAi renaissance is creating a new generation of startups (BioPharma Dive)
Oct-31-24 09:00AM	Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 (PR Newswire)
Oct-30-24 08:00AM	Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire)
Oct-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.41%
Oct-18-24 08:00AM	Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up (Investor's Business Daily)
Oct-04-24 07:00PM	Why Avidity Biosciences Zoomed to a 12% Gain This Week (Motley Fool) -7.08%
10:53AM	FDA lifts clinical hold on Aviditys lead antibody conjugate therapy trial (Pharmaceutical Technology)
07:00AM	Loading…
Oct-03-24 07:00AM	Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) (PR Newswire)
Sep-29-24 06:27AM	Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024? (Insider Monkey)
Sep-26-24 07:34PM	Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey) -8.23%
Sep-25-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Sep-23-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-05-24 09:00AM	Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month (PR Newswire)
Aug-28-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-20-24 07:44AM	Avidity, Kymera raise fresh funds; Walgreens partners with BARDA (BioPharma Dive)
Aug-19-24 09:00AM	Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Aug-14-24 08:30PM	Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +6.16%
Aug-13-24 04:01PM	Avidity Biosciences Announces Proposed Public Offering of Common Stock (PR Newswire)
Aug-09-24 08:53PM	RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace) +12.13% -5.26%
05:20PM	Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:17PM	How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics (Investor's Business Daily)
04:05PM	Loading…
04:05PM	Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
07:00AM	Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44 Trial (PR Newswire)
Aug-05-24 09:15AM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer (PR Newswire)
Jul-24-24 06:41AM	3 Stocks Doing Even Better Than Superstar Super Micro (SMCI) (InvestorPlace)
Jul-23-24 07:00AM	3 Russell 2000 Growth Stocks That Could Be Worth the Risk (Motley Fool)
Jul-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-03-24 06:53AM	Aviditys FSHD drug del-brax shows promise in Phase I/II trial (Clinical Trials Arena)
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-24 09:00AM	Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day (PR Newswire)
Jun-17-24 04:05PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jun-14-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Jun-13-24 08:00PM	Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock (PR Newswire)
10:39AM	Avidity (RNA) Up 33% on Rare Muscle Disease Study Results (Zacks)
Jun-12-24 04:04PM	The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record (Investor's Business Daily) +32.64%
04:01PM	Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
07:45AM	Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss (BioPharma Dive)
07:00AM	Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire)
May-29-24 04:05PM	Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress (PR Newswire)
08:45AM	2 Potentially High-Reward Growth Stocks to Buy Right Now (Motley Fool)
May-23-24 06:00AM	Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound (InvestorPlace) -7.26%
May-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-19-24 09:03AM	Bank of America Predicts up to ~200% Surge for These 2 Strong Buy Stocks (TipRanks)
May-17-24 03:24AM	Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing (MT Newswires)
May-15-24 09:00AM	Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors (PR Newswire)
May-09-24 11:55PM	RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
May-08-24 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
12:27PM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1 (MT Newswires)
06:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire)
Apr-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.29%
Apr-04-24 01:30AM	Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares (GuruFocus.com) -11.07%
Mar-27-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-15-24 07:01PM	Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA) (GuruFocus.com)
Mar-04-24 04:02PM	Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy (Investor's Business Daily) -6.22%
07:00AM	Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR Trial (PR Newswire)
Feb-29-24 12:00PM	Avidity Biosciences Honors Rare Disease Day (PR Newswire) +19.92%
07:00AM	Avidity Biosciences Announces Oversubscribed $400 Million Private Placement (PR Newswire)
Feb-28-24 05:20PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:40PM	Avidity Biosciences Inc (RNA) Reports Year-End Financials and Clinical Progress (GuruFocus.com)
04:05PM	Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights (PR Newswire)
Feb-27-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire) +5.51%
Feb-26-24 06:55AM	3 Highly Rated Biotech Stocks to Buy for 300% Gains (InvestorPlace)
Feb-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-20-24 09:00AM	Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Feb-15-24 05:00PM	Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Jan-29-24 08:54AM	Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Jan-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-05-24 08:30AM	Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth (PR Newswire)
Dec-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.10%
Dec-13-23 08:30AM	Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44 Trial for Duchenne Muscular Dystrophy (PR Newswire) +10.28%
Nov-29-23 09:03AM	Avidity (RNA) Expands Collaboration With BMY, Shares Rise (Zacks) +10.31%
Nov-28-23 10:09AM	Why Is Avidity Biosciences (RNA) Stock Up 15% Today? (InvestorPlace) +14.94%
10:02AM	Avidity Stock Soars on Collaboration Deal With Bristol Myers (Barrons.com)
07:01AM	Bristol Myers pours $100M into RNA drugs for cardiovascular diseases (BioPharma Dive)
06:30AM	Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology (PR Newswire)
Nov-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.63%
09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Nov-08-23 06:12PM	Avidity Biosciences Inc (RNA) Reports Third Quarter 2023 Financial Results and Recent Highlights (GuruFocus.com) -7.03%
04:05PM	Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
Oct-23-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.49%
Oct-07-23 07:30AM	Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 (PR Newswire)
Sep-26-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society (PR Newswire)
Sep-25-23 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Sep-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.33%
Sep-11-23 07:28PM	Down More Than 50%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound (TipRanks) +9.74%
Sep-07-23 09:00AM	Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs (PR Newswire)
Aug-31-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference (PR Newswire) -5.14%

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flanagan W. Michael	CSTO	Dec 18 '24	Sale	32.66	12,742	416,154	72,647	Dec 19 06:17 PM
MacLean Michael F	Chief Financial Officer	Dec 18 '24	Sale	32.66	11,151	364,192	82,942	Dec 19 06:16 PM
Boyce Sarah	President and CEO	Dec 18 '24	Sale	32.66	31,855	1,040,384	265,308	Dec 19 06:15 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 18 '24	Sale	32.66	11,151	364,192	82,867	Dec 19 06:15 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 16 '24	Option Exercise	14.22	25,000	355,500	119,018	Dec 18 04:46 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 16 '24	Sale	33.26	25,000	831,605	94,018	Dec 18 04:46 PM
TERESA MCCARTHY	Officer	Dec 16 '24	Proposed Sale	32.49	25,000	812,250		Dec 16 04:29 PM
Flanagan W. Michael	CSTO	Dec 11 '24	Option Exercise	22.47	24,000	539,280	109,389	Dec 13 06:08 PM
Flanagan W. Michael	CSTO	Dec 11 '24	Sale	35.77	24,000	858,401	85,389	Dec 13 06:08 PM
W. MICHAEL FLANAGAN	Officer	Dec 11 '24	Proposed Sale	36.10	24,000	866,400		Dec 11 04:59 PM
McCarthy Teresa	Chief Human Resources Officer	Nov 18 '24	Option Exercise	14.22	25,000	355,500	119,018	Nov 20 06:10 PM
McCarthy Teresa	Chief Human Resources Officer	Nov 18 '24	Sale	41.14	25,000	1,028,520	94,018	Nov 20 06:10 PM
LEVIN ARTHUR A	Director	Nov 19 '24	Option Exercise	1.24	3,323	4,121	18,153	Nov 20 06:06 PM
LEVIN ARTHUR A	Director	Nov 19 '24	Sale	42.12	3,323	139,973	14,830	Nov 20 06:06 PM
MacLean Michael F	Chief Financial Officer	Nov 06 '24	Option Exercise	8.43	79,057	666,064	159,275	Nov 08 04:50 PM
MacLean Michael F	Chief Financial Officer	Nov 06 '24	Sale	45.56	106,319	4,843,979	94,093	Nov 08 04:50 PM
MICHAEL MACLEAN	Officer	Nov 06 '24	Proposed Sale	45.09	106,319	4,793,924		Nov 06 04:56 PM
LEVIN ARTHUR A	Director	Oct 21 '24	Option Exercise	1.24	5,000	6,200	19,830	Oct 23 04:19 PM
LEVIN ARTHUR A	Director	Oct 21 '24	Sale	46.63	5,000	233,168	14,830	Oct 23 04:19 PM
ARTHUR A LEVIN	Director	Oct 21 '24	Proposed Sale	50.45	8,323	419,895		Oct 21 04:21 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 16 '24	Option Exercise	14.22	25,000	355,500	119,018	Oct 17 04:20 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 16 '24	Sale	48.52	25,000	1,213,010	94,018	Oct 17 04:20 PM
LEVIN ARTHUR A	Officer	Oct 16 '24	Proposed Sale	46.60	22,500	1,048,500		Oct 16 01:48 PM
Thompson Tamar	Director	Oct 07 '24	Option Exercise	27.63	30,000	828,900	30,000	Oct 09 05:23 PM
Thompson Tamar	Director	Oct 07 '24	Sale	44.98	30,000	1,349,259	0	Oct 09 05:23 PM
Thompson Tamar	Officer	Oct 07 '24	Proposed Sale	47.30	30,000	1,419,000		Oct 07 04:39 PM
Flanagan W. Michael	CSTO	Oct 01 '24	Option Exercise	26.75	62,500	1,671,875	147,889	Oct 03 04:09 PM
Flanagan W. Michael	CSTO	Oct 01 '24	Sale	47.62	62,500	2,976,112	85,389	Oct 03 04:09 PM
WILLIAM MICHAEL FLANAGAN	Officer	Oct 01 '24	Proposed Sale	45.93	38,018	1,746,167		Oct 01 04:36 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 23 '24	Sale	44.00	13,153	578,737	69,018	Sep 23 09:06 PM
Flanagan W. Michael	CSTO	Sep 23 '24	Sale	43.95	25,000	1,098,733	72,718	Sep 23 09:03 PM
Boyce Sarah	President and CEO	Sep 23 '24	Sale	44.00	32,880	1,446,723	234,663	Sep 23 09:01 PM
MacLean Michael F	Chief Financial Officer	Sep 23 '24	Sale	44.00	11,510	506,440	96,355	Sep 23 08:59 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 23 '24	Proposed Sale	44.48	36,329	1,615,914		Sep 23 04:27 PM
LEVIN ARTHUR A	Director	Sep 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Sep 20 05:19 PM
LEVIN ARTHUR A	Director	Sep 19 '24	Sale	45.73	5,000	228,658	14,830	Sep 20 05:19 PM
Flanagan W. Michael	CSTO	Sep 11 '24	Option Exercise	25.24	96,500	2,435,855	138,265	Sep 13 04:25 PM
Flanagan W. Michael	CSTO	Sep 11 '24	Sale	40.40	111,394	4,500,244	60,871	Sep 13 04:25 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 11 '24	Option Exercise	14.22	25,000	355,500	82,171	Sep 13 04:17 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 11 '24	Sale	40.40	25,000	1,010,042	57,171	Sep 13 04:17 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 11 '24	Proposed Sale	40.79	111,394	4,543,761		Sep 11 04:18 PM
TERESA MCCARTHY	Officer	Sep 11 '24	Proposed Sale	40.79	75,000	3,059,250		Sep 11 04:18 PM
LEVIN ARTHUR A	Director	Aug 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Aug 21 04:30 PM
LEVIN ARTHUR A	Director	Aug 19 '24	Sale	45.19	5,000	225,946	14,830	Aug 21 04:30 PM
Boyce Sarah	President and CEO	Aug 06 '24	Option Exercise	1.24	28,000	34,720	233,043	Aug 07 05:46 PM
Boyce Sarah	President and CEO	Aug 06 '24	Sale	43.35	28,000	1,213,822	205,043	Aug 07 05:46 PM
LEVIN ARTHUR A	Director	Jul 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Jul 23 04:22 PM
LEVIN ARTHUR A	Director	Jul 19 '24	Sale	45.01	5,000	225,069	14,830	Jul 23 04:22 PM
Boyce Sarah	President and CEO	Jul 09 '24	Option Exercise	1.24	28,000	34,720	233,043	Jul 11 04:07 PM
Boyce Sarah	President and CEO	Jul 09 '24	Sale	39.93	28,000	1,118,082	205,043	Jul 11 04:07 PM
LEVIN ARTHUR A	Director	Jun 20 '24	Option Exercise	1.24	5,000	6,200	19,830	Jun 21 04:19 PM
LEVIN ARTHUR A	Director	Jun 20 '24	Sale	37.59	5,000	187,950	14,830	Jun 21 04:19 PM
McCarthy Teresa	Chief Human Resources Officer	Jun 18 '24	Sale	39.13	9,864	385,972	32,171	Jun 20 06:49 PM
MacLean Michael F	Chief Financial Officer	Jun 18 '24	Sale	39.13	11,228	439,345	57,865	Jun 20 06:48 PM
Boyce Sarah	President and CEO	Jun 18 '24	Sale	39.13	32,074	1,255,040	142,543	Jun 20 06:47 PM
Flanagan W. Michael	CSTO	Jun 18 '24	Sale	39.13	10,106	395,445	50,765	Jun 20 06:47 PM
MacLean Michael F	Chief Financial Officer	Jun 12 '24	Option Exercise	8.82	104,245	919,441	148,338	Jun 14 07:07 PM
MacLean Michael F	Chief Financial Officer	Jun 12 '24	Sale	35.72	104,245	3,723,141	44,093	Jun 14 07:07 PM
LEVIN ARTHUR A	Director	Jun 13 '24	Sale	40.08	60,000	2,404,782	153,872	Jun 14 07:03 PM
LEVIN ARTHUR A	Director	Jun 12 '24	Sale	35.07	40,000	1,402,628	213,872	Jun 14 07:03 PM
Boyce Sarah	President and CEO	Jun 13 '24	Option Exercise	1.24	164,233	203,649	276,350	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 12 '24	Option Exercise	1.24	100,000	124,000	212,117	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 14 '24	Option Exercise	1.24	35,767	44,351	147,884	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 13 '24	Sale	40.08	164,233	6,581,802	112,117	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 12 '24	Sale	35.73	100,000	3,573,020	112,117	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 14 '24	Sale	40.08	35,767	1,433,484	112,117	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 04 '24	Option Exercise	1.24	28,000	34,720	140,117	Jun 05 05:46 PM
Boyce Sarah	President and CEO	Jun 04 '24	Sale	27.42	28,000	767,780	112,117	Jun 05 05:46 PM
LEVIN ARTHUR A	Director	May 20 '24	Option Exercise	1.24	5,000	6,200	19,830	May 21 05:05 PM
LEVIN ARTHUR A	Director	May 20 '24	Sale	29.90	5,000	149,481	14,830	May 21 05:05 PM
MacLean Michael F	Chief Financial Officer	May 14 '24	Option Exercise	8.82	75,000	661,500	119,093	May 16 06:25 PM
MacLean Michael F	Chief Financial Officer	May 14 '24	Sale	28.28	75,000	2,121,045	44,093	May 16 06:25 PM
Boyce Sarah	President and CEO	May 07 '24	Option Exercise	1.24	28,000	34,720	140,117	May 07 09:52 PM
Boyce Sarah	President and CEO	May 07 '24	Sale	25.54	28,000	715,050	112,117	May 07 09:52 PM
LEVIN ARTHUR A	Director	Apr 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Apr 22 05:28 PM
LEVIN ARTHUR A	Director	Apr 19 '24	Sale	22.82	5,000	114,123	14,830	Apr 22 05:28 PM
LEVIN ARTHUR A	Director	Apr 03 '24	Sale	27.11	20,000	542,214	253,872	Apr 03 08:26 PM
Boyce Sarah	President and CEO	Apr 02 '24	Option Exercise	1.24	28,000	34,720	140,117	Apr 03 06:16 PM
Boyce Sarah	President and CEO	Apr 02 '24	Sale	26.25	28,000	734,919	112,117	Apr 03 06:16 PM
LEVIN ARTHUR A	Director	Mar 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Mar 21 04:10 PM
LEVIN ARTHUR A	Director	Mar 19 '24	Sale	23.97	5,000	119,848	14,830	Mar 21 04:10 PM
MacLean Michael F	Chief Financial Officer	Mar 13 '24	Option Exercise	8.82	40,000	352,800	84,093	Mar 15 04:12 PM
MacLean Michael F	Chief Financial Officer	Mar 13 '24	Sale	24.52	40,000	980,760	44,093	Mar 15 04:12 PM
LEVIN ARTHUR A	Director	Mar 12 '24	Option Exercise	1.24	25,000	31,000	42,471	Mar 12 08:41 PM
LEVIN ARTHUR A	Director	Mar 12 '24	Sale	22.03	27,641	609,017	14,830	Mar 12 08:41 PM
Boyce Sarah	President and CEO	Mar 08 '24	Option Exercise	1.24	84,000	104,160	196,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 12 '24	Option Exercise	1.24	28,000	34,720	140,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 08 '24	Sale	21.39	84,000	1,796,710	112,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 12 '24	Sale	22.63	28,000	633,682	112,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 01 '24	Option Exercise	1.24	84,000	104,160	196,117	Mar 05 04:53 PM
Boyce Sarah	President and CEO	Mar 01 '24	Sale	20.13	84,000	1,691,306	112,117	Mar 05 04:53 PM
LEVIN ARTHUR A	Director	Jan 22 '24	Sale	10.13	1,859	18,832	17,471	Jan 23 03:14 PM
Boyce Sarah	President and CEO	Jan 22 '24	Sale	10.13	5,092	51,582	44,008	Jan 23 03:13 PM
Flanagan W. Michael	CSTO	Jan 22 '24	Sale	10.13	4,129	41,827	35,871	Jan 23 03:12 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 22 '24	Sale	10.13	2,065	20,918	17,035	Jan 23 03:11 PM
MacLean Michael F	Chief Financial Officer	Jan 22 '24	Sale	10.13	1,616	16,370	16,884	Jan 23 03:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNA

Avidity Biosciences Inc

Upgrade your FINVIZ experience